WORLDWIDE, access to appropriate drug treatments is limited and largely unplanned. Most limitations are economic, due to regional or personal poverty. In developing countries, for example, over 70% of those with epilepsy have no access to appropriate drug treatment.1 In the United States and other industrialized countries, powerful economic forces are increasingly setting limits to both group and individual access to antiepileptic drugs (AEDs).